ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADCT ADC Therapeutics SA

4.98
0.25 (5.29%)
Last Updated: 19:55:15
Delayed by 15 minutes
Share Name Share Symbol Market Type
ADC Therapeutics SA NYSE:ADCT NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 5.29% 4.98 5.105 4.81 4.96 266,002 19:55:15

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

07/11/2022 12:15pm

Business Wire


ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more ADC Therapeutics Charts.

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Investors Eugenia Litz ADC Therapeutics Eugenia.Litz@adctherapeutics.com +44 7879 627205 Amanda Loshbaugh ADC Therapeutics Amanda.Loshbaugh@adctherapeutics.com +1 917-288-7023 Media Mary Ann Ondish ADC Therapeutics Maryann.Ondish@adctherapeutics.com +1 914-552-4625

1 Year ADC Therapeutics Chart

1 Year ADC Therapeutics Chart

1 Month ADC Therapeutics Chart

1 Month ADC Therapeutics Chart

Your Recent History

Delayed Upgrade Clock